FRAMINGHAM, Mass., Sept. 6 /PRNewswire/ -- Bioheart, Inc. is focused on
the discovery, development and commercialization of cell-based therapy
products for the treatment of cardiovascular diseases. The Company's initial
autologous cell transplantation technology ("MyoCell") is designed to
regenerate functioning muscle in previously infarcted or non-functioning
myocardial tissue.
(Photo: http://www.newscom.com/cgi-bin/prnh/20010828/BIOLOGO )
The Company's two primary product offerings are:
1. Autologous cellular implants for regenerating heart muscle damaged
from a heart attack.
2. Proprietary endovascular device to implant cells in the heart.
Bioheart's cellular implants will address significant markets for disease
states such as congestive heart failure (4.6 million patients in the US) and
myocardial infarction (7.2 million patients).
Bioheart Technology
Myoblasts are an effective cell transplantation source for heart muscle
regeneration since they are committed to become muscle, are resistant to
ischemia, do not over proliferate and are able to assume cardiac workload.
Dr. Doris Taylor has demonstrated that myoblasts are fundamental to the
success of the procedure. Phillippe Menasche M.D. has conducted initial human
cases and has reported improvements in cardiac function, using autologous
myoblasts in a patient with a previous infarct.
INTELLECTUAL PROPERTY
US5130141 Law, Peter K. Compositions for and methods 7/14/92
Goodwin, Tena G. of treating muscle
degeneration and weakness
US5972013 Schmidt, Cecil C. Direct device with 10/26/99
deflecting mechanism
and method
US5580779 Smith, David A. Method for Inducing human 12/3/96
Townsend, Laurace myocardial cell proliferation
Newman, Dawn
Duff, Ronald G.
US5543318 Smith, David A. Method of Isolation, culture 8/6/96
Townsend, Laurace and proliferation of human
atrial myocytes
Financial Information
During 2001, Bioheart intends to advance its clinical progress and promote
foreign sales. Bioheart Inc. has recently completed a $15 million round of
Series B financing. Bioheart has also received a strategic financing from the
Guidant Corporation.
Forward Looking Information
This press release contains certain forward-looking statements which are
based on management's current expectations and are subject to uncertainties,
risks and changes in circumstances, many of which involve factors or
circumstances which are beyond Bioheart's ability to control.
SOURCE Bioheart, Inc.
 back to top
Related links:
http://www.bioheartinc.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/20010828/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Howard B. Haimes, Ph.D. Vice President of
Strategic Operations of Bioheart, Inc., +1-508-271-9930
|
